Research programme: transforming growth factor beta-1 antagonists - GlaxoSmithKline

Drug Profile

Research programme: transforming growth factor beta-1 antagonists - GlaxoSmithKline

Alternative Names: SB 431542; SB 505124

Latest Information Update: 24 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Benzamides; Dioxoles; Small molecules
  • Mechanism of Action Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Wounds

Most Recent Events

  • 06 Sep 2004 A preclinical study has been added to the Cancer pharmacodynamics section
  • 01 Sep 2004 A preclinical study has been added to the Skin disorders pharmacodynamics section
  • 01 Mar 2004 Preclinical trials in Wounds in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top